BIO KOREA 2023, co-hosted by the Korea Health Industry Development Institute (President Cha Soon-do, hereinafter referred to as the Agency) and Chungcheongbuk-do (Governor Kim Young-hwan), will be held for three days from May 2023 (Wed) to 5 (Fri) at COEX in Seoul ( Held at COEX, a conference will be held to introduce innovative technologies in line with the latest trends in the biohealth industry during the exhibition period.
After the pandemic, the importance of the biohealth industry has increased in terms of economic growth and public health protection, and changes in the biohealth industry are taking shape in various forms through digital innovation and convergence technology.
In line with these changes and the government’s policy of creating a new market for biohealth, BIO KOREA 2023 will share the latest technology trends and vision in the biohealth industry through various programs, including conferences, under the theme of ‘Hyper-connected era, leap to new growth innovative technology’. .
The conference will be held in 11 sessions on 21 topics including regenerative medicine, vaccines, and gene therapy, and about 13 speakers from 120 countries with master’s and doctoral degrees in the biohealth field will participate to share the latest issues and technology business trends encompassing the entire industry. It proceeds through discussion.
On the first day, the 10th (Wednesday), sessions on gene therapy, CDMO (Contract Development & Manufacturing Organization), and healthcare big data will be held, including the special session ‘Digital Transformation’.
In the ‘Digital Transformation’ session, starting with a presentation by Ryu Jae-jun, general director of Naver Cloud, a leading domestic medical cloud company, the current status of the digital transformation industry, investment trends, and success stories will be shared with numerous domestic and foreign speakers.
The ‘Gene Therapy’ session, which is in the spotlight as a next-generation new drug, explores global expansion strategies for domestic companies through the success stories of global companies, and the ‘CDMO’ session shares R&D outsourcing use cases and strategies of big pharma companies.
The ‘Healthcare Big Data’ session, which will be held over two days from Wednesday the 10th to Friday the 11th, will discuss the current status of the precision medicine service support system being created in accordance with the advancement of digitalization, production and analysis of healthcare big data, and related policies and policies. We share the status of government projects and discuss the direction of data activation and development.
On the second day, the 11th (Thursday), a special session will be held under the theme of ‘The New Normal of Clinical Trials’, introducing the latest research and development trends on the topics of vaccines, regenerative medicine, artificial intelligence new drug development, and healthcare big data. .
Focusing on changes in global clinical trial trends, starting with a presentation by special speaker Dr. Cynthia Verst of IQVIA, a new drug development clinical service company, trends in global clinical trials, including decentralized clinical trials, were shared and next-generation clinical trials Let’s look at ways to revitalize the country.
In the vaccine and regenerative medicine session, business groups carrying out national research and development (R&D) projects (Vaccine Commercialization Technology Development Team, New Variant Infectious Disease mRNA Vaccine Project Group, Pan-Ministry Regenerative Medicine Technology Development Team, etc.) and related organizations (Regenerative Medicine Promotion Foundation, Advanced Technology Development Group, etc.) Regenerative Medicine Industry Association, etc.), many researchers participate to examine the current status of research and development and explore utilization strategies and development directions for the industry.
In the artificial intelligence new drug development session, we will look at domestic and international cases of AI-based new drug development used from basic research to preclinical studies, and introduce the current status of commercialization of AI research products and patent strategies for protecting intellectual property rights.
On the last day, Friday the 12th, the ‘Blockbuster Patent Expiration’ session, ‘ADC (Antibody Drug Conjugate)’, and ‘Convergence Technology Medical Device’ sessions will be held.
The ‘Blockbuster Patent Expiration’ session introduces the patent status of blockbuster drugs and patent litigation precedents, and discusses response strategies for original and late-stage drugs following the expiration of patent terms. With the theme of Korea’s new approach to developing blockbuster ADC drugs, the ‘ADC’ session will share the current status of ADC research and development in the government, industry, and academia and explore successful ADC development strategies in Korea.
The ‘Convergence Technology Medical Device’ session will discuss the latest trends in micro-nanorobots, a new concept medical device, as well as technology development and commercialization for each disease.
In addition, various detailed programs such as side sessions, business partnering, exhibitions, and investment fairs will be held at Bio Korea 2023. Participation applications and detailed information can be found on the Bio Korea 2023 website.